SG Americas Securities LLC Acquires Shares of 68,374 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

SG Americas Securities LLC bought a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 68,374 shares of the company’s stock, valued at approximately $866,000. SG Americas Securities LLC owned approximately 0.07% of Day One Biopharmaceuticals at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. FMR LLC lifted its stake in Day One Biopharmaceuticals by 178.5% during the 3rd quarter. FMR LLC now owns 7,412,380 shares of the company’s stock valued at $103,254,000 after acquiring an additional 4,750,936 shares during the period. Braidwell LP boosted its holdings in Day One Biopharmaceuticals by 60.5% in the third quarter. Braidwell LP now owns 4,873,853 shares of the company’s stock worth $67,893,000 after purchasing an additional 1,837,949 shares during the last quarter. Vestal Point Capital LP grew its position in Day One Biopharmaceuticals by 100.0% in the 3rd quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock worth $34,825,000 after purchasing an additional 1,250,000 shares during the period. First Turn Management LLC purchased a new stake in Day One Biopharmaceuticals during the 3rd quarter valued at $13,204,000. Finally, Maverick Capital Ltd. lifted its holdings in shares of Day One Biopharmaceuticals by 74.5% during the 3rd quarter. Maverick Capital Ltd. now owns 2,114,006 shares of the company’s stock valued at $29,448,000 after buying an additional 902,868 shares during the period. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 11,245 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $16.03, for a total transaction of $180,257.35. Following the completion of the transaction, the insider now owns 1,085,790 shares in the company, valued at $17,405,213.70. This trade represents a 1.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders have sold 51,745 shares of company stock valued at $748,567. 8.40% of the stock is currently owned by insiders.

Day One Biopharmaceuticals Stock Up 3.4 %

Shares of Day One Biopharmaceuticals stock opened at $13.21 on Wednesday. Day One Biopharmaceuticals, Inc. has a 52 week low of $11.13 and a 52 week high of $18.07. The stock’s 50-day simple moving average is $12.82 and its 200-day simple moving average is $13.81. The company has a market capitalization of $1.33 billion, a price-to-earnings ratio of -12.83 and a beta of -1.46.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.58. The company had revenue of $93.76 million for the quarter, compared to analysts’ expectations of $15.05 million. During the same period in the previous year, the business posted ($0.54) earnings per share. On average, equities analysts expect that Day One Biopharmaceuticals, Inc. will post -0.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, January 13th. Bank of America dropped their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $35.86.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.